Life Sciences issue 2023 highlights companies making a difference with their research
Read the full interview with Dr. Rupalla in which she discusses Ymmunobio's activities and achievements.
top of page
Presentation to focus on mechanism of action of anti-tumor activity for lead asset YB-200
RIEHEN, SWITZERLAND, April 26, 2023 ─ Ymmunobio, a preclinical stage biotech company specializing in the development of innovative treatments for cancer patients, has been selected to present findings from its lead asset YB-200 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) on May 4, 2023.
Ymmunobio CEO Dr. Katrin Rupalla said, “It’s an honor to participate in Europe’s largest meeting focused on cancer immunotherapy research and development. We look forward to sharing results from our research into the mechanism of action of our monoclonal antibody YB-200. This is a great opportunity to discuss our science and answer any questions.”
TITLE: "YB-200, a novel IgG1 antibody targeting CEACAM1/5, induces complete response in syngeneic liver Hepa1-6 tumor-bearing mice and modulates the immune response"
POSTER NUMBER: #197
FIRST AUTHOR: Michel Janicot, PhD, CDO, Ymmunobio
TIME: Thursday, 4 May 2023 between 3:30 pm - 6:00 pm.
CIMT invites international participants for high-level scientific exchange, collaboration, and education focused on cancer immunotherapy.
This year’s plenary speakers at CIMT represent the leading scientists and researchers from around the world and include Lisa Meier McShane, PhD, Associate Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute, U.S. National Institutes of Health; Marcela Maus, MD, Associate Professor at Harvard Medical School, the Paula O’Keefe Chair in Oncology and Director of Cellular Immunotherapy at Massachusetts General Hospital (MGH) Cancer Center; Stefan Fröhling, MD, Head of the Division of Translational Medical Oncology at the German Cancer Research Center; Anne Rios, MD, group leader and head of the imaging center of the Princess Maxima Center for Pediatric Oncology, Ultrecht, Netherlands; and Rob Manguso, PhD, Assistant Professor of Medicine in the Massachusetts General Hospital Cancer Center and Harvard Medical School and an Associate Member in the Cancer Program at the Broad Institute of MIT and Harvard.
ABOUT YMMUNOBIO
Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments focus on high unmet need indications in gastro-intestinal cancers. Learn more on Ymmunobio’s website and follow on LinkedIn.
Investor Relations: Dr. Katrin Rupalla, info@ymmuno.bio
Martin E. Zuzulo to guide drug development operations for preclinical-stage biotech company
RIEHEN, SWITZERLAND, April 11, 2023 – Ymmunobio, a preclinical stage biotech company specializing in the development of innovative treatments for cancer patients, announced today that it has appointed Martin E. Zuzulo as its new Chief Operating Officer. Zuzulo steps in for Interim COO Peter Schiemann, PhD, who remains as Chairman of the Board for Ymmunobio.
“Marty’s substantial industry, consulting, and business development experience is a great asset for our team,” said Ymmunobio Founder and CEO Katrin Rupalla. “We’re delighted that he has joined the executive team and will be helping to advance our strategy for our novel and first-in-class antibody research.”
“I’m very impressed with the foundational research that Ymmunobio has undertaken to support its plans for drug development and delivery,” said Zuzulo. “Ymmunobio’s assets are positioned to provide powerful therapies in the fight against cancer, and I’m honored to be a part of this esteemed group.”
Zuzulo’s career has been focused on helping biopharmaceutical and medical device companies improve their R&D capabilities, focusing on their quality, clinical, and regulatory environments, as well as their GxP operations. He previously served in manufacturing and process development roles at Biogen and in executive positions across both industry-specific (Parexel) and life sciences practices at several leading management consulting organizations (IBM, PwC, Accenture).
Zuzulo earned his B.S. and B.A. in Biological Sciences (Biochemical Engineering Minor) and Psychology from Stony Brook University in Stony Brook, NY.
Ymmunobio recently was granted Orphan Drug Designation (ODD) by the US Food & Drug Administration (FDA) for YB-200, a CEACAM1/5 antibody it is studying for the treatment of hepatocellular carcinoma (HCC). “This designation is an important milestone in our development of CEACAM antibodies as anti-cancer treatments,” said Dr. Rupalla. The company has also begun developing the lead, fully humanized and first-in-class NPTXR antibody, YB-800, which has demonstrated anti-tumor activity in vivo and in vitro for solid tumors, including several gastro-intestinal and breast cancers.
To learn more about Ymmunobio’s activities and research, visit the website or reach out to info@ymmuno.bio.
ABOUT YMMUNOBIO
Ymmunobio AG is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making extensive progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation. Learn more on Ymmunobio’s website and follow on LinkedIn.
Investor Relations: Dr. Katrin Rupalla, info@ymmuno.bio
bottom of page